Healthcare and life sciences

Walder Wyss Ltd.

Hailed as the ‘best pharma regulatory team in Switzerland’, Walder Wyss Ltd. houses a broad offering which acts on both contentious and non-contentious pricing-focused mandates, hospital planning proceedings, and strategic collaboration agreements. Michael Isler leads the team alongside Andreas Wildi, who stands out due to his vast knowledge of domestic and international reimbursement and pricing issues surrounding medical devices, and pharmaceutical and blood products. Key members of the team include Annemarie Lagger, who is particularly adept at handling supply chain and market access issues, and Celine Weber, who is recommended for her expertise in pharma advertising work.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘The teams are highly specialised and extremely pragmatic. The solutions are always delivered within the agreed timeframe and in the required level of detail.’
‘Celine Weber: Always reachable, very professional and pragmatic. I would recommend her to anyone in the healthcare sector!’
‘Best pharma regulatory team in Switzerland in my experience.’
‘Andreas Wildi is extremely knowledgeable and responsive.’
‘Walder Wyss has a strong track record in advising clients in the life sciences and biotechnology sectors. This expertise is crucial for a company like ours, which operates in the biopharmaceutical services field. The firm's lawyers understand the specific regulatory, commercial, and intellectual property challenges that biotech companies face.’
‘Huge expertise within the team, both from a legal but also medical aspect, which contributes to a deeper understanding of the healthcare system.’
‘Strong network and, thus, a good understanding of how authorities work. The combination of legal and medical backgrounds allows them to understand topics on a deeper level.’
‘A well-coordinated team that quickly recognises clients' needs and develops concrete, feasible and useful procedures. Andreas Wildi and Annemarie Lagger have excellent specialist knowledge at the highest level.’

Key clients

Amgen Switzerland AG
Pfizer AG
Hirslanden Group
University Children's Hospital Zurich
A. Menarini GmbH
Stemline Therapeutics Switzerland GmbH
Max Zeller Söhne AG
Grünenthal Pharma AG
BeiGene Switzerland AG
Laboratorium Dr. G. Bichsel AG
MediService AG
Siemens Healthcare
Healthineers
Vereinigung Pharmafirmen in der Schweiz
Der Verband für Optometrie und Optik (association for optometry and optics)
Verein Berufliche Grundbildung Augenoptik VBAO
OrPha Swiss GmbH
Schweizerischer Apothekerverband PharmaSuisse
PharmaBiome AG
MySmartHeart AG
PEDeus AG
Permamed AG
Schweizerische Gesellschaft für Porphyrie
ASSGP - Schweizerischer Fachverband für Selbstmedikation
Pierre Fabre Pharma AG
ExcellGene SA
Medgate AG
Ymmunobio AG
Institute of Molecular and Clinical Ophthalmology Basel
Alentis Therapeutics AG
BC Platforms AG
Quant Biomarkers AG
Epicelya Therapeutics AG
PAGE Therapeutics AG
Versant Ventures
Adjuvant Capital
SIS Medical AG

Work highlights

Represented Pfizer, Amgen, Pierre Fabre and A. Menarini in various price reduction proceedings before the Federal Administrative Court and successfully represented Grünenthal Pharma before the Swiss Federal Supreme Court.
Representing Hirslanden Group in hospital planning proceedings in numerous Swiss Cantons as well as in several inter-cantonal planning proceedings in the field of highly specialised medical services before the competent inter-cantonal planning body and the Federal Administrative Court.
Advised SixPeaks Bio on its funding (USD 110m) by AstraZeneca, among other matters.